Cargando…
Riociguat in children with pulmonary arterial hypertension: The PATENT–CHILD study
Riociguat, a soluble guanylate cyclase stimulator, is approved for treatment of adults with pulmonary arterial hypertension (PAH). The safety, tolerability, and pharmacokinetics (PK) of oral riociguat in a pediatric population with PAH was assessed in PATENT–CHILD (NCT02562235), a multicenter, singl...
Autores principales: | García Aguilar, Humberto, Gorenflo, Matthias, Ivy, D. Dunbar, Moledina, Shahin, Castaldi, Biagio, Ishida, Hidekazu, Cześniewicz, Paweł, Kusa, Jacek, Miera, Oliver, Pattathu, Joseph, Weng, Ken‐Pen, Ablonczy, Laszlo, Apitz, Christian, Katona, Marta, Kurosaki, Kenichi, Pulido, Tomas, Yamagishi, Hiroyuki, Yasuda, Kazushi, Cisternas, Galia, Goth, Melanie, Lippert, Susanne, Radomskyj, Anna, Saleh, Soundos, Willmann, Stefan, Wirsching, Gabriela, Bonnet, Damien, Beghetti, Maurice |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485817/ https://www.ncbi.nlm.nih.gov/pubmed/36186721 http://dx.doi.org/10.1002/pul2.12133 |
Ejemplares similares
-
Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015) -
Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies
por: Stephan, Rosenkranz, et al.
Publicado: (2015) -
Treatment of pediatric pulmonary arterial hypertension: A focus on the NO‐sGC‐cGMP pathway
por: Beghetti, Maurice, et al.
Publicado: (2019) -
Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
por: Frey, Reiner, et al.
Publicado: (2017) -
Approaching the 50(th) anniversary of the first Fontan procedure. What is the current state of treatment provided to patients with functional single ventricles?
por: Cześniewicz, Paweł J., et al.
Publicado: (2017)